Drs. Mannion and Geier 6/28/2017

Dr. MannionDr. Mannion was raised in Pennsylvania, attended the Massachusetts Institute of Technology (MIT), where he majored in chemical engineering. He then continued with parallel clinical and research training at the New York University School of Medicine, simultaneously receiving an MD and a PhD.

He completed an internship and residency in internal medicine at Brigham & Women's Hospital and a fellowship in medical oncology at Dana Farber Cancer Institute both in Boston, Mass

Dr. Mannion has been practicing medical oncology full time in Cincinnati since 1997. He provides care for all types of malignancies but has a special interest in genitourinary cancers which include cancers of the prostate, bladder, testicles, and kidneys. He was one of the founders of the Prostate Cancer Collaborative at Christ Hospital, a multidisciplinary program where patients are seen simultaneously by several prostate cancer specialists to optimize their care.

Dr. Mannion also has an interest in hospital administration. He serves as the medical director of oncology services at The Christ Hospital Health Network, overseeing operations of the oncology service line. He also sits on various hospital committees at the administrative level. He sees patients at the Red Bank location in Cincinnati and at the Fort Wright location in Northern Kentucky.

Board Certification

American Board of Internal Medicine - Medical Oncology

American Board of Internal Medicine - Internal Medicine


New York University School of Medicine(Professional Education)

Brigham and Women's Hospital(Internship Program)

Brigham and Women's Hospital(Residency Program)

Harvard Medical School(Fellowship Program)

Specialties as they relates to Prostate Cancer

The primary job of a medical oncologist is managing cancer. Most medical oncologists think of themselves as more than just chemotherapy doctors. In fact most medical oncologists wear many hats.

Contact Information

The Christ Hospital outpatient center 1955 Dixie Hwy, Suite G ChristHospitalLogo

Fort Wright, KY 41011

(859) 331-3304


  • Active Surveillance for very low risk and for low risk disease
  • Options after Prostatectomy if T3, positive margin, or measurable PSA
  • Androgen Deprivation and cognitive decline
  • Statins in castrate sensitive prostate cancer
  • Docetaxel in castrate sensitive prostate cancer (and high risk disease)
  • Olaparib in castrate resistant prostate cancer



  • Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
    • Laurence Klotz, Danny Vesprini, Perakaa Sethukavalan, Vibhuti Jethava, Liying Zhang, Suneil Jain, Toshihiro Yamamoto, Alexandre Mamedov, and Andrew Loblaw

Journal of Clinical Oncology Volume 33,  Jan 20, 2015:272-27

  • Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer

Jeffrey J. Tosoian, Mufaddal Mamawala, Jonathan I. Epstein, Patricia Landis, Sacha Wolf, Bruce J. Trock, and H. Ballentine Carter

Journal of Clinical Oncology Volume 33 Oct 20, 2015:3379-3385

  • Course and Predictors of Cognitive Function in Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Controlled Comparison
    • Brian D. Gonzalez, Heather S.L. Jim, Margaret Booth-Jones, Brent J. Small, Steven K. Sutton, Hui-Yi Lin, Jong Y. Park, Philippe E. Spiess, Mayer N. Fishman, and Paul B. Jacobsen

Journal of Clinical Oncology Volume 33 Jun 20, 2015:2021-2027

  • Androgen Deprivation Therapy and Future Alzheimer’s Disease Risk
    • Kevin T. Nead, Greg Gaskin, Cariad Chester, Samuel Swisher-McClure, Joel T. Dudley, Nicholas J. Leeper, and Nigam H. Shah

Journal of Clinical Oncology Volume 34  Feb 20, 2016:566-571



DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer

Joaquin Mateo, M.D., Suzanne Carreira, Ph.D., Shahneen Sandhu, M.D., Susana Miranda, B.Sc., Helen Mossop, M.Math.Stat., Raquel Perez-Lopez, M.D., Daniel Nava Rodrigues, M.D., Dan Robinson, Ph.D., Aurelius Omlin, M.D., Nina Tunariu, M.D.Res., Gunther Boysen, Ph.D., Nuria Porta, Ph.D., Penny Flohr, B.Sc., Alexa Gillman, B.Sc., Ines Figueiredo, B.Sc., Claire Paulding, B.Sc., George Seed, M.Sc., Suneil Jain, M.D., Christy Ralph, M.D., Andrew Protheroe, M.D., Ph.D., Syed Hussain, M.D., Robert Jones, M.D., Ph.D., Tony Elliott, M.D., Ph.D., Ursula McGovern, M.D., Ph.D., Diletta Bianchini, M.D., Jane Goodall, B.Sc., Zafeiris Zafeiriou, M.D., Chris T. Williamson, Ph.D., Roberta Ferraldeschi, M.D., Ph.D., Ruth Riisnaes, F.I.B.M.S., Bernardette Ebbs, B.T.E.C., Gemma Fowler, B.Sc., Desamparados Roda, M.D., Wei Yuan, Ph.D., Yi-Mi Wu, Ph.D., Xuhong Cao, M.S., Rachel Brough, Ph.D., Helen Pemberton, Ph.D., Roger A’Hern, Ph.D., Amanda Swain, Ph.D., Lakshmi P. Kunju, M.D., Rosalind Eeles, M.D., Ph.D., Gerhardt Attard, M.D., Ph.D., Christopher J. Lord, Ph.D., Alan Ashworth, Ph.D., Mark A. Rubin, M.D., Karen E. Knudsen, Ph.D., Felix Y. Feng, M.D., Ph.D., Arul M. Chinnaiyan, M.D., Ph.D., Emma Hall, Ph.D., and Johann S. de Bono, M.B., Ch.B., Ph.D.

N Engl J Med 2015; Volume 373:1697-1708 October 29, 2015


Statin Use at the Time of Initiation of Androgen Deprivation Therapy and Time to Progression in Patients With Hormone-Sensitive Prostate Cancer 

Lauren C. Harshman, MD; Xiaodong Wang, PhD; Mari Nakabayashi, MD; Wanling Xie, MS; Loana Valenca, MD; Lillian Werner, MS; Yongjiang Yu, PhD; Aaron M. Kantoff, BS; Christopher J. Sweeney, MBBS; Lorelei A. Mucci, ScD; Mark Pomerantz, MD; Gwo-Shu Mary Lee, PhD; Philip W. Kantoff, MD1Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
2Gelb Center for Translational Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
3Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, Massachusetts
4Department of Urology, Shanghai Jiao Tong University School of Medicine, Xinhua Hospital, Shanghai, China
5Apple Tree Partners, New York, New York
6Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts

JAMA Oncol. July 2015;Volume1(4):495-504


Power Point Slides Only